Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Non-proteolytic ubiquitination of Hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion

Hong-Jen Lee, Chien-Feng Li, Diane Ruan and 5 more (opens in a new tab)

Nature Communications · 2019 · CC BY

doi:10.1038/s41467-019-10374-y (opens in a new tab)

Abstract

Enormous efforts have been made to target metabolic dependencies of cancer cells for developing new therapies. However, the therapeutic efficacy of glycolysis inhibitors is limited due to their inability to elicit cell death. Hexokinase 2 (HK2), via its mitochondrial localization, functions as a central nexus integrating glycolysis activation and apoptosis resilience. Here we identify that K63-linked ubiquitination by HectH9 regulates the mitochondrial localization and function of HK2. Through stable isotope tracer approach and functional metabolic analyses, we show that HectH9 deficiency impedes tumor glucose metabolism and growth by HK2 inhibition. The HectH9/HK2 pathway regulates cancer stem cell (CSC) expansion and CSC-associated chemoresistance. Histological analyses show that HectH9 expression is upregulated and correlated with disease progression in prostate cancer. This work uncovers that HectH9 is a novel regulator of HK2 and cancer metabolism. Targeting HectH9 represents an effective strategy to achieve long-term tumor remission by concomitantly disrupting glycolysis and inducing apoptosis.

References 70

  1. 1.

    Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491:364-373.

    Not in our library10.1038/nature11706 (opens in a new tab)

  2. 2.

    Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat. Rev. Cancer. 2016;16:635-649.

    Not in our library10.1038/nrc.2016.77 (opens in a new tab)

  3. 3.

    Pavlova NN, Thompson CB. The emerging Hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47.

    Not in our library10.1016/j.cmet.2015.12.006 (opens in a new tab)

  4. 4.

    Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-563.

    Not in our library10.1038/nature13490 (opens in a new tab)

  5. 5.

    Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 2016;41:211-218.

    Not in our library10.1016/j.tibs.2015.12.001 (opens in a new tab)

  6. 6.

    Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol. Cell. 2016;61:667-676.

    Not in our library10.1016/j.molcel.2016.02.011 (opens in a new tab)

  7. 7.

    Sciacovelli M, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016;537:544-547.

    Not in our library10.1038/nature19353 (opens in a new tab)

  8. 8.

    Letouze E, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23:739-752.

    Not in our library10.1016/j.ccr.2013.04.018 (opens in a new tab)

  9. 9.

    Amoedo, N. D., Obre, E. & Rossignol, R. Drug discovery strategies in the field of tumor energy metabolism: limitations by metabolic flexibility and metabolic resistance to chemotherapy. Biochimica et Biophysica Acta1858, 674–685 (2017).

    Not in our library10.1016/j.bbabio.2017.02.005 (opens in a new tab)

  10. 10.

    Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22:248-257.

    Not in our library10.1038/cdd.2014.173 (opens in a new tab)

  11. 11.

    Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol. 2003;206:2049-2057.

    Not in our library10.1242/jeb.00241 (opens in a new tab)

  12. 12.

    Deng Y, Lu J. Targeting hexokinase 2 in castration-resistant prostate cancer. Mol. Cell. Oncol. 2015;2:e974465.

    Not in our library10.4161/23723556.2014.974465 (opens in a new tab)

  13. 13.
    Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer · 2016
    No notice
  14. 14.

    Suh DH, et al. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin. Exp. Med. 2014;14:345-353.

    Not in our library10.1007/s10238-013-0250-9 (opens in a new tab)

  15. 15.
    Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin · 2018
    Corrected
  16. 16.

    Patra KC, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213-228.

    Not in our library10.1016/j.ccr.2013.06.014 (opens in a new tab)

  17. 17.

    Wang L, et al. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 2014;8:1461-1474.

    Not in our library10.1016/j.celrep.2014.07.053 (opens in a new tab)

  18. 18.

    Tait, S. W. & Green, D. R. Mitochondrial regulation of cell death. Cold Spring Harbor Perspect. Biol.5, 513 (2013).

    Not in our library10.1101/cshperspect.a008706 (opens in a new tab)

  19. 19.

    Vyssokikh MY, Brdiczka D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta Biochim. Pol. 2003;50:389-404.

    Not in our library

  20. 20.
    Subcellular Localization of Hexokinases I and II Directs the Metabolic Fate of Glucose · 2011
    No notice
  21. 21.

    Mattiroli F, Sixma TK. Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways. Nat. Struct. Mol. Biol. 2014;21:308-316.

    Not in our library10.1038/nsmb.2792 (opens in a new tab)

  22. 22.

    Lee HJ, et al. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. Mol. Cell. 2016;63:1021-1033.

    Not in our library10.1016/j.molcel.2016.08.009 (opens in a new tab)

  23. 23.

    Chen D, et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell. 2005;121:1071-1083.

    Not in our library10.1016/j.cell.2005.03.037 (opens in a new tab)

  24. 24.

    Chen D, Brooks CL, Gu W. ARF-BP1 as a potential therapeutic target. Br. J. Cancer. 2006;94:1555-1558.

    Not in our library10.1038/sj.bjc.6603119 (opens in a new tab)

  25. 25.

    Kon, N., Zhong, J., Qiang, L., Accili, D. & Gu, W. Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice. J. Biol. Chem.287, 5102–5111 (2012).

    Not in our library10.1074/jbc.m111.322867 (opens in a new tab)

  26. 26.

    Adhikary S, et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell. 2005;123:409-421.

    Not in our library10.1016/j.cell.2005.08.016 (opens in a new tab)

  27. 27.

    Wu HT, et al. K63-polyubiquitinated HAUSP deubiquitinates HIF-1alpha and dictates H3K56 acetylation promoting hypoxia-induced tumour progression. Nat. Commun. 2016;7:13644.

    Not in our library10.1038/ncomms13644 (opens in a new tab)

  28. 28.

    TeSlaa T, Teitell MA. Techniques to monitor glycolysis. Methods Enzym. 2014;542:91-114.

    Not in our library10.1016/b978-0-12-416618-9.00005-4 (opens in a new tab)

  29. 29.

    Wolf A, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 2011;208:313-326.

    Not in our library10.1084/jem.20101470 (opens in a new tab)

  30. 30.

    Botzer LE, et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br. J. Cancer. 2016;114:759-766.

    Not in our library10.1038/bjc.2016.26 (opens in a new tab)

  31. 31.

    Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell. 2008;14:10-21.

    Not in our library10.1016/j.ccr.2008.06.001 (opens in a new tab)

  32. 32.

    Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25:4683-4696.

    Not in our library10.1038/sj.onc.1209595 (opens in a new tab)

  33. 33.

    Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490.

    Not in our library10.1016/s0092-8674(00)81589-5 (opens in a new tab)

  34. 34.

    Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 2014;21:196-205.

    Not in our library10.1038/cdd.2013.139 (opens in a new tab)

  35. 35.

    Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem. 2002;277:7610-7618.

    Not in our library10.1074/jbc.m109950200 (opens in a new tab)

  36. 36.

    Majewski N, et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell. 2004;16:819-830.

    Not in our library10.1016/j.molcel.2004.11.014 (opens in a new tab)

  37. 37.

    Canfield K, et al. Inverse association between MDM2 and HUWE1 protein expression levels in human breast cancer and liposarcoma. Int J. Clin. Exp. Patho. 2016;9:6342-6349.

    Not in our library

  38. 38.

    Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H. Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol. Cell Biol. 2008;28:1007-1017.

    Not in our library10.1128/mcb.00224-07 (opens in a new tab)

  39. 39.

    Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 2008;15:521-529.

    Not in our library10.1038/sj.cdd.4402285 (opens in a new tab)

  40. 40.
    Akt Phosphorylates HK-II at Thr-473 and Increases Mitochondrial HK-II Association to Protect Cardiomyocytes · 2013
    No notice
  41. 41.

    Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin. Cancer Biol. 2015;31:16-27.

    Not in our library10.1016/j.semcancer.2014.06.004 (opens in a new tab)

  42. 42.

    Chen CL, et al. NANOG Metabolically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism. Cell Metab. 2016;23:206-219.

    Not in our library10.1016/j.cmet.2015.12.004 (opens in a new tab)

  43. 43.

    Dong C, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316-331.

    Not in our library10.1016/j.ccr.2013.01.022 (opens in a new tab)

  44. 44.

    Diehn M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780-783.

    Not in our library10.1038/nature07733 (opens in a new tab)

  45. 45.

    Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J. Bioenerg. Biomembr. 2008;40:171-182.

    Not in our library10.1007/s10863-008-9148-8 (opens in a new tab)

  46. 46.

    Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc. Natl Acad. Sci. USA. 2012;109:20491-20496.

    Not in our library10.1073/pnas.1206530109 (opens in a new tab)

  47. 47.
    Tumor cell‐specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase · 2014
    No notice
  48. 48.

    Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol. 2017;14:11-31.

    Not in our library10.1038/nrclinonc.2016.60 (opens in a new tab)

  49. 49.

    Liu T, et al. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. Cell Death Dis. 2014;5:e1470.

    Not in our library10.1038/cddis.2014.431 (opens in a new tab)

  50. 50.

    Pollak M. Potential applications for biguanides in oncology. J. Clin. Investig. 2013;123:3693-3700.

    Not in our library10.1172/jci67232 (opens in a new tab)

  51. 51.

    Raez LE, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013;71:523-530.

    Not in our library10.1007/s00280-012-2045-1 (opens in a new tab)

  52. 52.

    Wang L, et al. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine. 2016;7:50-61.

    Not in our library10.1016/j.ebiom.2016.03.022 (opens in a new tab)

  53. 53.

    Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer. 2008;8:51-56.

    Not in our library10.1038/nrc2274 (opens in a new tab)

  54. 54.

    Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472-482.

    Not in our library10.1016/j.ccr.2008.05.005 (opens in a new tab)

  55. 55.

    Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555-566.

    Not in our library10.1016/j.cell.2016.07.002 (opens in a new tab)

  56. 56.

    Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 2005;65:10545-10554.

    Not in our library10.1158/0008-5472.can-05-1925 (opens in a new tab)

  57. 57.

    Bhattacharya B, Mohd Omar MF, Soong R. The Warburg effect and drug resistance. Br. J. Pharmacol. 2016;173:970-979.

    Not in our library10.1111/bph.13422 (opens in a new tab)

  58. 58.

    Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532.

    Not in our library10.1038/cddis.2013.60 (opens in a new tab)

  59. 59.

    Martinez-Outschoorn UE, et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle. 2011;10:1271-1286.

    Not in our library10.4161/cc.10.8.15330 (opens in a new tab)

  60. 60.

    Zhao Z, et al. PKM2 promotes stemness of breast cancer cell by through Wnt/beta-catenin pathway. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016;37:4223-4234.

    Not in our library10.1007/s13277-015-4121-8 (opens in a new tab)

  61. 61.

    Le Gal K, et al. Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med. 2015;7:308re308.

    Not in our library10.1126/scitranslmed.aad3740 (opens in a new tab)

  62. 62.

    Sayin VI, et al. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 2014;6:221ra215.

    Not in our library10.1126/scitranslmed.3007653 (opens in a new tab)

  63. 63.

    Lawenda BD, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J. Natl Cancer Inst. 2008;100:773-783.

    Not in our library10.1093/jnci/djn148 (opens in a new tab)

  64. 64.

    Klein EA, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549-1556.

    Not in our library10.1001/jama.2011.1437 (opens in a new tab)

  65. 65.

    Dominguez-Brauer C, et al. Mule regulates the intestinal stem cell niche via the Wnt pathway and targets EphB3 for proteasomal and lysosomal degradation. Cell Stem Cell. 2016;19:205-216.

    Not in our library10.1016/j.stem.2016.04.002 (opens in a new tab)

  66. 66.

    Inoue S., Hao Z., Elia A. J., Cescon D., Zhou L., Silvester J., Snow B., Harris I. S., Sasaki M., Li W. Y., Itsumi M., Yamamoto K., Ueda T., Dominguez-Brauer C., Gorrini C., Chio I. I. C., Haight J., You-Ten A., McCracken S., Wakeham A., Ghazarian D., Penn L. J. Z., Melino G., Mak T. W. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes & Development. 2013;27(10):1101-1114.

    Not in our library10.1101/gad.214577.113 (opens in a new tab)

  67. 67.

    Montal ED, et al. PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth. Mol. Cell. 2015;60:571-583.

    Not in our library10.1016/j.molcel.2015.09.025 (opens in a new tab)

  68. 68.

    Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 2011;300:C723-C742.

    Not in our library10.1152/ajpcell.00462.2010 (opens in a new tab)

  69. 69.

    Chin RM, Panavas T, Brown JM, Johnson KK. Optimized mitochondrial targeting of proteins encoded by modified mRNAs rescues cells harboring mutations in mtATP6. Cell Rep. 2018;22:2818-2826.

    Not in our library10.1016/j.celrep.2018.02.059 (opens in a new tab)

  70. 70.
    Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy · 2008
    No notice

Cited by papers we hold 6

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.